Tarsus Pharmaceuticals Inc Announces FDA Acceptance Of Investigational New Drug

Tarsus Pharmaceuticals Inc Announces Fda Acceptance Of

tarsus pharmaceuticals inc is a late clinical stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients

Tarsus Pharmaceuticals Inc Announces Type C Meeting With

currently there are no fda approved treatments for demodex blepharitis about tarsus pharmaceuticals inc tarsus pharmaceuticals inc is a late clinical stage

Tarsus Pharmaceuticals Gets Fda Greenlight For Tp 05 Lyme

tarsus pharmaceuticals nasdaq tars announces that the u s fda has accepted the company s investigational new drug ind application for tp 05 an oral non vaccine

Tarsus Pharmaceuticals Inc Reports Full Year 2020 Financial

enrollment complete for saturn 1 first tp 03 pivotal trial for the treatment of demodex blepharitis initiation of saturn 2 expected in q2 2021 strategic partnership

Tarsus Pharmaceuticals Announces Positive Results Of The Mars

irvine calif june 15 2020 prnewswire tarsus pharmaceuticals a clinical stage biopharmaceutical company today announced positive results of its phase 2a mars